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Abstract: We evaluated 6 different porcine zona pellucida (PZP) preparations used as a
single-shot vaccine for multiyear contraception of captive white-tailed deer (Odocoileus virginianus). The study compared 2 PZP preparation technologies from ImmunoVaccine Technologies™ (IVT) and National Wildlife Research Center (NWRC) over a 7-year period. The
study compared both the use of oil in an emulsion and in suspension delivery, as well as
replacement of the oil with an alum adjuvant. The study demonstrated that the oil emulsion
adjuvant provided the longest lasting response. PZP isolated by the IVT provides a longerlasting response than the preparation used by NWRC. The SpayVacTM and IVT-PZP vaccines
presented in an emulsion form with AdjuVac™ produce a single-shot immunocontraceptive
vaccine lasting up to 7 years.
Key words: human–wildlife conflicts, immunocontraception, Odocoileus virginianus, porcine
zona pellucida, single-shot PZP vaccine, white-tailed deer
Immunocontraceptive vaccines prevent
conception by stimulating production of antibodies that bind with and neutralize proteins
or hormones essential for reproduction (Curtis et al. 2008, Miller et al. 2008). Porcine zona
pellucida (PZP) vaccines prepared using zonae
pellucida isolated from pig ovaries are one of
the most studied immunocontraceptive vaccines in wildlife. The zona pellucida is a cellular glycoprotein layer surrounding the mammalian oocyte. During fertilization, sperm bind
to receptors on the outer surface of the oocyte
and penetrate the zona pellucida. Anti-PZP antibodies block sperm binding and penetration
into the ovum and may also interfere with follicle maturation and ovulation (Dunbar 1989,
Aitken et al 1996). Females treated with PZP
vaccines typically experience multiple infertile
estrous cycles throughout the breeding season
(Killian and Miller 2000, Miller and Killian 2000,
Miller et al. 2000). PZP vaccines have been used
to contracept feral horses (Equus caballus; Kirpatrick et al. 1990, Kirpatrick et al. 1992), whitetailed deer (Odocoileus virginianus; Curtis et al.
2007, Killian et al. 2008, Rutberg and Naugle
2008), coyotes (Canis latrans; Miller et al. 2006),

domestic sheep (Ovis aries; Stoops et al. 2006),
and captive exotic species (Frank et al. 2005).
Based on the encouraging results of early
investigations, we began studies with the PZP
vaccine in white-tailed deer during 1992. We
hoped to develop a single-shot contraceptive
vaccine that was safe for the animals and had
multiyear eﬃcacy. White-tailed deer were then,
as they are now, of interest as a target species
because of inadequate control methods available to deal with dense urban and suburban
deer populations in the northeastern United
States (Hussain et al. 2007, Bissonettee et al.
2008, DeNicola and Williams 2008, Mastro and
Conover 2008, Ng et al. 2008).
In an early study, we immunized white-tailed
deer with a 1-ml injection containing 500-μg
PZP in Freund’s Complete Adjuvant™ (FCA)
followed by multiple booster injections, each
with 1-ml injection containing 300-μg PZP in
Freund’s Incomplete Adjuvant™ (FIA). In the
first year, the prime dose was given in August
and 2 boosts were given in September and October. In November, the does were exposed to
bucks. In the second year, does were given 1 or
2 boosts, depending on their current PZP titer.
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We continued the study for 4 more years without additional boosts. The does exhibited 100%
contraception the first year, 89% over 3 years,
and 76% over 6 years (Miller and Killian 2000).
Given the multiple injections and the high dose
of PZP required to induce infertility, we recognized that this approach was not practical
for field applications. In a later field study, we
showed that a prime and boost of 100 ug of PZP
emulsified in FCA and FIA could provide multiyear contraception (Curtis et al. 2008).
Few studies have reported that a single-injection vaccine can provide immunization with effectiveness up to 2 years (Fraker et al. 2002, Liu
et al. 2005, Locke et al. 2007, Turner et al. 2007,
Rutberg and Naugle 2008). In mice, a single injection with a vaccine containing influenza viral peptides and adjuvant (Adjumer®) in mice
caused antibody titers to increase gradually
up to 6 months, but titers began to decline at
9 months (Payne et al. 1995). Their study suggested that for infertility to be achieved with a
single injection, the vaccination would need to
be given months before the onset of reproductive activity (i.e., the rut period) so that an adequate titer level could develop for contraception to occur.
Adjuvants are critical in vaccines for the development of high antibody titers in response
to vaccination. Our work on a new adjuvant began in 1998 after learning that the U.S. Food and
Drug Administration (FDA) would not approve
the use of vaccines containing FCA because this
adjuvant was associated with significant reactions at the site of injection. Consequently, we
developed a new oil-based adjuvant called
AdjuVac, containing <200 μg of killed Mycobacterium avium per dose. M. avium is a common
nonpathogenic bacterium to which most wildlife and domestic animals worldwide have been
exposed.
The experiments described in the current paper represent the last phase of the study conducted with the PZP vaccine in white-tailed
deer. The objectives of the study was to compare the eﬀectiveness of 6 diﬀerent single shot
vaccine formulations, containing diﬀerent PZP
preparations and diﬀerent adjuvants or delivery systems.
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Methods

Deer Research Center at Pennsylvania State University
White-tailed deer used in this study were
born, raised, and maintained at the Pennsylvania
State University (PSU) Deer Research Center. The
original source of animals for the PSU deer herd
was the free-roaming white-tailed deer population from central Pennsylvania. During our
study, the PSU deer facility encompassed 54 ha
of natural forest habitat and was divided into 9
outdoor paddocks ranging in size from 0.1 to
1.5 ha. Vegetation on the open areas consisted
of a mixture of clover and orchard grasses, but
most of the land was covered with dense eastern deciduous forest that had little understory
vegetation. Deer were kept at a density of 25
to 37 animals per ha. During the nonbreeding
season, treated female deer were isolated from
males. To test vaccine contraceptive eﬃcacy, 4
bucks of proven sire ability were confined with
the does each year from the first week of November through the end of the following February.

PZP vaccine preparations
The heat-soluble PZP preparation used for the
PZP was prepared by Dr. Irwin Liu (University
of California at Davis) following the method
described by Dunbar and Raynor (1980). PZP
was provided to NWRC in phosphate buﬀered
saline (PBS ) buﬀer at a protein concentration of
1 mg/ml. It was used in either a 200-μg or 500μg protein dose prepared as an emulsion with
AdjuVac for administration in a 1-ml volume.
This preparation will henceforth be referred to
as NWRC-PZP.

ImmunoVaccine Technologies™
(IVT) PZP vaccine preparations
ImmunoVaccine Technologies™ (IVT) of
Halifax, Nova Scotia, Canada, developed the
IVT-PZP preparation using the Yurewicz et al.
(1983) procedure to isolate zona. This method
is similar to that described by Dunbar and
Raynor (1980). The IVT procedure consisted of
homogenizing the ovaries in Tris buﬀer by passage through a commercial meat grinder. The
resulting oocytes were cleared from cellular debris by successive passages of the ground tissue
through a series of nylon screens of decreasing pore size. The oocytes were then passed
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through a homogenizer to release the zona pellucida. We emulsified this PZP with AdjuVac to
create the IVT-PZP vaccine. We used SpayVac
(an IVT-PZP preparation encapsulated in liposomes; Brown et al. 1997) in 3 other vaccine
preparations. These were SpayVac emulsified
with AdjuVac, lypohilized SpayVac suspended
in AdjuVac, and SpayVac mixed with alum as
the adjuvant.

Experimental design
We divided 30 deer into 6 treatment groups
of 5 does each (Table 1). The first 4 treatment
groups were vaccinated with variations of the
IVT-PZP preparation. Group 1 was vaccinated
with SpayVac (IVT-PZP encapsulated in liposomes) suspended in AdjuVac. Group 2 was vaccinated with IVT-PZP (without the liposomes)
suspended in AdjuVac. Group 3 was vaccinated
with lyophilized SpayVac suspended in AdjuVac. Group 4 received SpayVac combined with
alum. Lyophilized (freeze-dried) vaccine used
in Group 3 evaluated whether a suspension
would produce a long-lasting contraceptive
eﬀect like that seen with the emulsion in the
standard vaccine preparations. The SpayVac in
alum used in Group 4 was intended to evaluate
the utility of alum suspension as an adjuvant
for producing long-term contraception.
All IVT-PZP-treated deer were vaccinated
with 200 μg of PZP that contained approximately 35% protein. The IVT-PZP preparation
contained some precipitate that became part of
the vaccine preparation. Groups 5 and 6 were
vaccinated with 200-μg and 500-μg doses, respectively, of NWRC-PZP as measured by Low-
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ry assay. Vaccines were prepared by producing
a 1:1 emulsion volume:volume with AdjuVac.
We administered all PZP vaccine formulations in mid-July 2000. We took 10 ml of blood
from does in all groups except for Group 2,
which was vaccinated during July 2001. Fawning data were available for untreated does exposed to bucks in the Penn State herd during
each year of study. While these does were not
sham-treated, they were handled in the summer and fall, as were the treated does, when
they received health vaccinations. We considered the fawning rates of the untreated does to
represent normal fertility rates for does in the
Penn State herd.

Laboratory methods
We collected 10 ml of blood by jugular venipuncture from the study deer in July, September, November, and February. We used the
sample to determine antibody titers, progesterone levels, and pregnancy-specific protein B in
samples collected in February. Anti-PZP titers
for groups using IVT-PZP and the NWRC-PZP
200 μg/dose as the antigen were determined
by ELISA at the IVT laboratories. This method
reports the titer as a percentage of a standard
rabbit anti-PZP titer, which is considered 100%
(Brown et al. 1997).
Anti-PZP titers for the NWRC-PZP 500 μg/
dose vaccine were measured, using ELISA at
the NWRC laboratories. Titers were calculated
as the last serial dilution in which the treated
sample was at least twice the absorbance of the
pretreated sample of the same animal. In the
NWRC laboratory method to determine anti-

Table 1. Experimental design defining the nature of the vaccine treatments and adjuvants.
Groups 1–4 represent PZP produced by IVT mixed with diﬀerent adjuvant preparations. Groups 4
and 5 represent 200 and 500 μg of PZP from NWRC, both made into an emulsion.
Group

Vaccine Treatment

Liposomes

Adjuvant

Adjuvant-Vaccine
Mixture

1

IVT-PZP(200 μg)—SpayVac

Yes

AdjuVac

Emulsion

2

IVT-PZP(200 μg)

No

AdjuVac

Emulsion

3

IVT-PZP(200 μg)—SpayVaclyophilized

Yes

AdjuVac

Suspension

4

IVT-PZP(200 μg)—SpayVac

Yes

Alum

Suspension

5

NWRC-PZP(200 μg)

No

AdjuVac

Emulsion

6

NWRC-PZP(500 μg)

No

AdjuVac

Emulsion
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body titers, 100 ng of PZP antigen was placed
in each well of a micro-titer plate. Sea BlockTM
(Pierce Chemical, Rockford, Ill.) was used to
prevent binding of antibodies to the plastic in
the ELISA plate. Deer serum was serially diluted from 1:1,000 to 1:128,000 in PBS containing
Sea Block. Antibodies in the deer serum to the
native PZP antigen on the plate were directed
with the following linkages: deer anti-PZP
binds to PZP on the plate, rabbit anti-deer IgG
binds to the deer IgG, goat anti-rabbit-peroxidase binds to the rabbit IgG. Tetramethylbenzidine was used to develop the color, and 2M
H2SO4 was used to stop the reaction. The color
intensity of the sample was read at 450 nm with
a Dynatech MR 5000 ELISA plate reader.
Plasma progesterone levels were assayed by
the coat-a-tube RIA method (Diagnostic Products, Los Angeles, Calif.), following the manufacturer’s recommended procedure. Assays
for Pregnancy-Specific Protein B (PSPB) were
performed by ELISA on samples submitted to
BioTracking LLC (Moscow, Ida.).

ties, including sniﬃng genitalia, pursuit of the
female, aggressive guarding, and copulation
(Killian and Miller 2000).

Ultrasonography and fawning data
We performed trans-rectal ultrasonography
in late January or early February of each year
to determine which does were in the first trimester of gestation. Blood drawn on the same
day was tested for progesterone concentration
and PSPB. From May through September, does
were observed daily for evidence of fawning.
We recorded fawning dates and the number
of fawns born and compared them to observations on behavioral estrus to estimate the date
of conception.

Definitions of contraception and
fertility

Does that were exposed to bucks and showed
signs of estrus, but did not fawn were considered contracepted or infertile. Does in each
group were monitored for contraceptive longevity and remained on the study until they
Behavioral observations
had twins. Does >2 years old and having 1 fawn
We monitored estrous cycles in deer to deter- were assumed to be sub-fertile because this is
mine the frequency of estrus and to learn about less than the average fawning rate of 2 fawns in
the mechanism of multiyear contraception. untreated does in the Penn State herd.
To determine when the does were in estrus,
Results
trained observers monitored the behavior of
bucks toward the treated does. Three observa- Contraception
The average fawning rate of the Penn State
tion periods of >30 minutes each were scheduled daily from November 7 through February herd for 84 untreated does from 2001 through
12, followed by 2 periods daily until February 2007 was 1.8 fawns per doe, with an average
28. Behavioral activity by the buck was record- doe age of 4 years (Table 2). Number of fawns
ed on an observation sheet for a range of activi- born varied with does age. For 2-year-olds, the
Table 2. Fawning data for untreated does in the Penn State University deer herd during the same years that the
contraceptive trial was conducted.
% does with
2 or more
fawns

Average doe
age

% does with 1
fawn

9

4.0

67

33

1.4

26

3.1

23

77

1.8

8

4.7

13

87

2.0

10

4.2

20

80

2.0

13

4.2

0

100

2.0

0

8

4.6

13

87

1.9

0

10

4.5

20

80

1.8

Year

% infertile

1

0

2

0

3

0

4

0

5

0

6
7

n

Average
fawns/doe
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average number of fawns born was 1.7. For
does >2 years old, the average number of fawns
born was 2.0.
Groups 1 and 2, which combined SpayVac or
IVT-PZP into an emulsion with AdjuVac, had
the longest contraceptive eﬀect, with 80% of
the deer contracepted for 5 to 7 years (Table 3).
Unfortunately, Group 1 was terminated after
5 years because of lack of funding, with 80%
of the treated deer still contracepted. One doe
in Group 2 had twins in year three and was
dropped from the study. In year five, 1 of the 4
remaining does in this group had a single fawn,
reducing the rate of contraception to 60%. However, because the birth of a single fawn did not
represent a complete breakthrough from immunological contraception, all 4 does were kept
for another year. In years six and seven, the doe
that had a fawn in year five did not fawn, restoring the contraception rate to 80% (Table 2).
Does in Group 3 were all contracepted in
the first year, one of the 4 does conceived the
second year, two of the 4 does had fawns during the third year, and all fawned during the
fourth year (Table 3). Consequently, this group
was dropped from the study at the end of year
four.
Four of the 5 does in Group 4 each had 1
fawn in the first year (Table 3). Consequently,
this group was removed from the study after
the first year. Groups 5 and 6 received 200 μg
and 500 μg of NWRC-PZP, respectively, in an
emulsion made with AdjuVac. For Group 5, 1
doe had 2 fawns the first year, for an 80% contraception rate (Table 3). However, because all
5 does produced 2 fawns in the second year,
Group 5 (200 μg of NWRC-PZP) was subsequently removed from the study. Does receiving 500 μg of PZP were 100% contracepted the
first year, but 4 of 5 does produced fawns the
second year (Table 3). This 20% contraception
rate remained until year five, when the remaining doe produced 2 fawns.
The number of fawns that could be produced
by the diﬀerent groups, had they not be contracepted, was estimated from the average fawning rates of untreated does in the herd during
the same years. This estimate of fecundity for
the 5 years when Group 1 was on the study was
46 fawns compared to 64 fawns for 7 years of
study with Group 2 (Table 3). Considering that

107
actual numbers of fawns produced for these 2
groups during the periods of study were 2 and
4 respectively, fecundity was reduced greater
than 90% by the vaccines containing IVT-PZP.

Antibody titers
Comparing the anti-PZP titers of all of the
groups, Group 1 (SpayVac; Figure 1a) had the
greatest initial immune response of all groups,
with a peak antibody titer at 18 months and a
titer of 80 to 100% of the rabbit standard during the first 2 years. Although the titer began to
drop after 18 months, it was sustained at 40%
to the end of the 5-year study. The rise in antibody titer for Group 2 IVT-PZP (Figure 1b) was
slower than that observed for Group 1, but by
year three, both groups had similar titers. The
antibody response patterns for Group 2, and to
a lesser extent for Groups 1 and 3, included a
self-boosting of titers, which was evident as titers increased without additional antigen injections (Figures 1a and 1b). Notably, for Groups
1 and 2, the high rates of contraception were
maintained even with lower titers in years four
through seven.
Deer in Group 3 that were given freeze-dried
SpayVac suspended in AdjuVac, were 100%
contracepted in the first year, but contraception rates dropped oﬀ to 75%, 50%, and 0% in
years two, three, and four, respectively (Table
3). Titers for Group 3 were high through year
two, but dropped in years three and four (Figure 1c), indicating that freeze-dried SpayVac in
suspension was less eﬀective for long-term contraception than the non-freeze-dried emulsion
form of SpayVac. SpayVac with alum adjuvant
produced a large variation in the immune responses, and only 1 doe produced a good immune response (Figure 2a).
Titers for Group 5, (200-μg NWRC-PZP mixed
with AdjuVac) were relatively high in the first
year (Figure 2a), with an 80% contraception
rate. However, average titers dropped dramatically in year two, and all of the does conceived.
Antibody titers determined for Group 6, treated with (500-μg NWRC-PZP mixed with AdjuVac™) were very high immediately after injection, but declined over the next 2 years (Figure
2b). In contrast to the IVT-PZP used in Groups
1 and 2 (Figures 1a and 1b), the NWRC-PZPtreated does in Groups 5 and 6 did not appear

–
–

–

–

Year 6

Year 7

1

1

1
–

–

3

–

2

0

0

Females

75

8

–

–

6

–

2

0

0

Fawns

Group 3
Lyophilized
SpayVac-AdjuVac
n=4

–

–

–

–

–

–

4

Females

43

4

–

–

–

–

–

–

4

Fawns

n=5

Group 4
SpayVac-Alum

–

–

–

–

–

5

1

Females

25

12

–

–

–

–

–

10

2

Fawns

Group 5
NWRC-PZP (200
μg)-AdjuVac
n=5

–

–

5

4

4

4

0

Females

74

12

–

–

2

2

2

6

0

Fawns

Group 6
NWRC-PZP (500
μg)-AdjuVac
n=5

NWRC preparations

1
Fecundity = expected rate of fawn production for the number of does in the treatment group for the duration of the study, using the average fawning rates of
untreated does (Table 2) for the same years. Percentage reduction in fecundity was determined by dividing the diﬀerence between the expected fawning rate
and the actual fawning rate by the expected fawning rate.

% Reduction in fecundity1

1

1

1

2

1

94

1

1

Year 5

1

1

96

1

1

0

0

6

0

0

Year 4

1

0

Fawns

2

0

0

Year 2

Year 3

Total
fawns

0

0

Year 1

Females

n=5

n=5
Fawns

Group 2
IVT-PZP-AdjuVac

Group 1
SpayVac-AdjuVac

Females

Fawning
Year

IVT PZP preparations

Table 3. Number of contracepted female deer that gave birth and number of fawns produced by them. All does were given a single vaccine dose of 200 μg on
July 10, 2000, except Group 3 does, which were immunized in July 2001.
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Figure 1a. Group 1: Ab
titer (PZP Lipo06sp).
SpayVac as an emulsion with AdjuVac.
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Figure 1b. Group 2: Ab titer
(PXPb200spwpd). IVT-PZP
as an emulsion with AdjuVac.
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Figure 1c. Group 3:
SpayVac, freeze-dried, as a
suspension in AdjuVac.
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Figure 1d. Group 4: SpayVac
absorbed onto alum.
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Figure 1, a–d. Each group represents a different PZP with different adjuvant preparations and delivery
methods. Antibody titers are presented as a percentage of a 100% anti-PZP rabbit standard. July 2000
to February 2006 represents the month-years post treatment throughout the study. The graph ends at the
point that all deer in the group became pregnant and the group was dropped from the study. Each data
point represents the mean ± SE.
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Figure 2a. Group 5:
200 μg of NWRCPZP presented as
an emulsion with AdjuVac, antibody titer
presented as a percentage of a rabbit
standard as 100%.
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Figure 2b. Group 6:
500 μg of NWRCPZP presented as
an emulsion with
AdjuVac antibody
titer presented as a
1/1000 –1/256,000
serial dilution end
point.
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Figure 2 a–b. Groups 5 and 6 represent 2 concentrations of the NWRC-PZP vaccine serial dilution end
point. July 2000 is the date of the vaccination, with July 2000 to February 2006 as the months and years of
post-treatment throughout the study. The graph ends at the point that all deer in the group became pregnant, and the group was dropped from the study. Each data point represents the mean (±SE).

to stimulate self-boosting, and the decreasing
of antibody titers (Figures 2a and 2b) resulted
in greater pregnancy rates in subsequent years
(Table 3).

Behavioral observations
PZP-treated deer had multiple estrous cycles
every year of the 5-year study, with the multicycling ceasing only when they became pregnant. The number of estrus events for all PZPtreated deer ranged from 1.5 to 3.0 per season,
with an average breeding season length of 150
days. This compares to 0.2 to 0.5 estrus events
for does in the untreated herd and an average
breeding period of 42 days per season. The 4
does in IVT-PZP Group 2 averaged 1.75 estrus
events in year seven of the trial, demonstrating
that cycling was still occurring, although none
of the does had fawns.

Progesterone and pregnancyspecific protein B determinations
Blood samples taken from deer anually in

July, September, November, and February were
assayed for serum progesterone concentrations. Despite the fact that the PZP-treated deer
showed signs of estrus and breeding behaviour during November and December, the only
consistent elevation in serum progesterone
observed was in the February blood samples
of SpayVac Group 1, IVT-PZP Group 2, and
NWRC-PZP 500-μg Group 6 (Figures 3a, 3b and
3c). This consistent increase in serum progesterone in February in the PZP-treated does was
not associated with pregnancy.
Blood serum was taken from 6 adult, proven-breeder does that were not bred during the
2006–2007 breeding season. Because these unbred, untreated does showed a similar elevation of serum progesterone in February (5.6 ±
0.4 SE), we concluded that this elevation of progesterone may be normal for cycling, nonpregnant does as they return to an anestrous state in
the nonbreeding season.
In contrast to serum progesterone concentrations, PSPB levels with a mean of 0.3 (non-

PZP vaccine • Miller et al.

111
Figure 3a.
Group1: Progesterone data
of SpayVac
presented as
μg/ml.
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Figure 3b.
Group 2:
Progesterone
data IVT-PZP
presented as
ng/ml.
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Figure 3c.
Group 6: Progesterone data
of NWRC 500
μg presented as
ng/ml.
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Figure 3 a–c. Progesterone peaks present in the January–February bleed in the SpayVac group (3a), the
IVT group (3b), and the 500-μg NWRC group (3c). July 2000 to February 2006 represents the month and
years of post-treatment throughout the study. Each data point represents the mean (±SE).

pregnant values >1.0) were well-correlated Injection-site reactions
There were no injection-site reactions in any
with ultrasound and fawning results. The PSPB
levels were correlated with fawning (r = 0.83, P of the treatment groups observed throughout
the study.
<0.0001).

Human–Wildlife Conflicts 3(1)

112

Discussion
This is the first study of a single-injection PZP
vaccine for white-tailed deer that results in contraception rates of 80% for 5 to 7 years. Based on
the performances of the diﬀerent vaccine preparations, it is clear that the long-lasting contraceptive eﬀect is related to the vaccine design
and the adjuvant used. The longest contraceptive eﬀect was achieved in Groups 1 and 2 that
included PZP produced by IVT and was made
into an emulsion with the NWRC adjuvant AdjuVac. Both of these groups showed periodic
boosting of the antibody titer, which may be
central to the long-lasting contraceptive eﬀect.
Because the PZP-contracepted does continued to cycle throughout the 7-year study, we
conclude that successful PZP immunocontraception depends on long-lasting, high titers
of high-aﬃnity antibodies and is unlikely the
result of PZP-immune complexes resulting in
ovarian damage.
The immune system is unable to maintain the
high antibody responses for long periods in the
absence of a stimulating antigen. Therefore, for
a successful immunocontraceptive response,
the antigen must be retained in the immune
system for months or years (Burton et al. 1994).
The follicular dendritic cells in the lymph node
that drains the site of injection may provide
an answer for the long-term immune response
found with some antigens. To induce immunocontraception that lasts months to years, there
must be a continued stimulation of these B-cells
by the injected antigen (Burton et al. 1994).

NWRC-PZP preparations performed well only
for 1 to 2 years.

Adjuvants

The oil-based adjuvant AdjuVac was an important component of the single-injection vaccine, contributing to both the antibody titer
produced and the long-term contraceptive response. The benefit of AdjuVac was clearly evident when we compared it to the poor response
when alum was used as the adjuvant.
The liposomes in SpayVac increased the longterm contraceptive eﬀect in other studies and
species. In this study, the IVT-PZP performed
almost as well as the SpayVac, although it is
possible that the addition of AdjuVac diminished the need for the liposomes in SpayVac.
Presumably, the liposomes facilitated a significant immune response when the vaccine was
combined with a less-eﬀective adjuvant.
Multi-year contraceptive eﬀectiveness has occurred in gray seals (Halichoerus grypus; Brown
et al. 1997), fallow deer (Dama dama; Fraker et
al. 2002), and white-tailed deer (Odocoileus virginianus; Locke et al. 2007) as a result of a single administration of SpayVac using Freund’s
Complete Adjuvant. For horses, Liu et al. (2005)
demonstrated a multiyear contraceptive eﬀect
when PZP was injected with Freund’s adjuvant,
and Turner et al. (2007) also was able to achieve
a multiyear contraceptive eﬀect with PZP in a
slow-release microbead. However, in the Liu
and Turner studies, the contraceptive eﬀect
was limited to 2 years, as we observed with the
NWRC-PZP prepared by Liu, which is considAntigen preparation
erably less than the 5–7 years achieved with the
Diﬀerences between the methods used to IVT-PZP in this study.
harvest oocytes for the IVT and NWRC antigen
preparations may have aﬀected the length of Emulsion
This study showed that an adjuvant prepared
contraceptive response. For the NWRC preparation, the oocytes in the ovaries were cleanly with the antigen in the form of an emulsion proreleased by 2 beds of 500 razor blades, which vides longer lasting contraception than that obenabled the rapid isolation of oocytes with min- served with a suspension of freeze-dried PZP.
imal disruption of other ovarian tissue. In con- The antigen administered in a single dose must
trast, for the IVT preparation, the ovaries were be retained in the body long enough to produce
processed in a meat grinder as the initial step specific antibodies that will bind with the antifor isolating the oocytes. Although most of the gen to form immune complexes (Bachmann et
remaining steps were similar, the initial mate- al. 1996). It appears that a stiﬀ emulsion (similar
rial in the IVT preparation probably contained to mayonnaise) is important for the retention of
more ovarian tissue. In contrast to the long-term the intramuscular dose of vaccine.
eﬃcacy achieved with the IVT-PZP groups, the
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The seasonal breeder: endogenous
PZP antigen results in self-boosting
It is possible that the success of the PZP-IVT
vaccines is aﬀected by the fact that deer are a
seasonal multicycling animal. Each season
when does enter a breeding condition, it is likely that the zona pellucida antigen is presented
to the immune system, resulting in a self-boosting eﬀect. It is possible the particulate nature of
the IVT-PZP preparations resulted in a longerboosting eﬀect and contributed to the longer
contraceptive eﬀect. There does not appear to
be any long-term negative health eﬀect from
the PZP contraception (Miller et al. 2001).
Immunocontraception holds the promise to
help resolve deer–human conflicts (Bingham
2007). The possibility of a single-injection PZP
contraceptive that would be eﬀective as a contraceptive for multiple years increases the usefulness of an injectable contraceptive for the
reproductive control of wildlife.
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